GSK stock consolidates as share buyback program remains on track

Traders Union
All News
Financial News
GSK slips 0.13% to GBX1872.50 today

Highlights

GSK reiterated its 2024 outlook for profitable growth following a stable Q1, with £1.4 billion in cash generated and net debt unchanged at 1.4x EBITDA.
Share buyback plans are progressing as promised, with the dividend from ViiV delivering a non-recurring lift to free cash flow.
The stock trades below key short- and medium-term averages, exhibiting bearish momentum and is expected to consolidate between GBX 1,845 and GBX 1,915 over the next week.

Shareholder returns maintained as cash flows offset by selling pressure

GSK held its first-quarter earnings call and reaffirmed its previous guidance for profitable growth in 2024, maintaining a steady outlook over the reported period. The company generated GBP 1.4 billion of cash in the quarter, leading to no change in net debt, which remained at 1.4 times EBITDA, while free cash flow saw a one-off boost due to a special ViiV dividend. Management also confirmed that the share buyback program remains on track, fulfilling its shareholder return commitments for the period, though price action has remained under broader selling pressure.

Oversold momentum deepens as key resistance caps recovery

On the technical front, GSK is trading below both the MA-20 (GBX 2,057.32) and MA-50 (GBX 2,067.21), while holding above the MA-200 at GBX 1,794.14. The Ichimoku Kijun line at GBX 2,023.75 marks a key resistance level. Momentum readings are weak: MACD and ADX both display sell signals, and the RSI at 29.54, Stoch RSI at 11.05, and CCI at -135.98 all point to oversold conditions. The BBP at -88.08 underscores persistent seller dominance, and the Awesome Oscillator aligns with the prevailing downward momentum. Intraday, GSK traded between GBX 1,870.00 and GBX 1,882.50, showing low volatility with a slight decline after the open.

Sideways trade expected as downside scenarios outweigh bullish risks

Over the next five trading days, GSK is likely to remain in a corridor between GBX 1,845 and GBX 1,915, reflecting typical volatility around current levels. Weekly technical signals indicate less than a 20% probability of a strong upward price shift, with downside scenarios more likely if support near GBX 1,845 is breached. The base case calls for continued sideways movement within this defined range. A confirmed break above the immediate resistance at GBX 2,024 would be required to open a bullish path, while a move below the lower support may trigger further selling.

Anton Kharitonov, expert at Traders Union, sees GSK maintaining a stable operational outlook after confirming guidance and solid cash generation in Q1. Price momentum remains weak, with technicals skewed to the downside and little evidence of near-term recovery. The base case is sideways to lower in the GBX 1,845–1,915 corridor unless resistance at GBX 2,024 is reclaimed. "Unless we see a break above GBX 2,024, further upside looks unlikely and short-term risk favors the bears."

Earlier, analysts noted that GSK was exhibiting ongoing technical weakness, with downside risks dominating its short-term outlook despite stable fundamentals. With momentum still negative and the shares holding just above crucial long-term support, traders should closely watch for a confirmed break below GBX 1,845, which could signal a new round of selling pressure in the days ahead.

Source of Data: GSK Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.